| | American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006The American Gastroenterological Association (AGA) convened a panel of gastroenterologists expert in the area of inflammatory bowel disease (IBD) that developed this consensus statement based on expert presentations of current scientific knowledge about IBD and through subsequent group discussion. This statement reflects the panel’s assessment of medical knowledge available when written. Thus, readers should view this statement in the context of data that will accumulate after its creation. The opinions, conclusions, and recommendations expressed in this report are those of the consensus panel members and may or may not reflect the official opinion of the American Gastroenterological Association Institute. The conference upon which this report is based was funded through an unrestricted educational grant from Abbott Laboratories. Abbott Laboratories representatives did not attend the conference, nor did they participate in any way in the development of this report. Abbreviations used in this paper: ADE, adverse drug event, CRP, C-reactive protein, EOW, every other week, FDA, Food and Drug Administration, PML, progressive multifocal leukoencephalopathy, TB, tuberculosis, TNF, tumor necrosis factor ⁎ Department of Pathology, Cambridge University, Cambridge, England ‡ Clin Des Maladies De L Apparei, Hopital Huriez Chru, Lille, France § Robarts Clinical Trials, London, England ∥ Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada ¶ Medicine/Gastroenterology & Nutrition, The University of Chicago, Chicago, Illinois # St. Mark’s Hospital, Harrow, England ⁎⁎ Center for Immunology, Mount Sinai Medical Center, New York, New York ‡‡ Freelance Medical Writer, Pittsburgh, Pennsylvania §§ University Hospital Gasthuisberg, Leuven, Belgium ∥∥ IBD Interest Group, Mayo Clinic, Gastroenterology and Hepatology, Rochester, Minnesota ¶¶ Clinical Research, Massachusetts General Hospital, Andover, Massachusetts ## Department of General Internal Medicine, Christian-Albrechts-University, Kiel, Germany ⁎⁎⁎ Division of Gastroenterology & IBD Center, Cedars-Sinai Medical Center, Los Angeles, California ‡‡‡ John Radcliffe Hospital, Gastroenterology Unit, Oxford, England  Address requests for reprints to: Stephen B. Hanauer, MD, and Paul Rutgeerts, MD, C/O of the AGA Institute National Office, 4930 Del Ray Avenue, Bethesda, Maryland 20814. Fax: (301) 654-5920.
Participants in the conference have indicated they have the following financial relationships with companies that market drugs and devices to gastroenterologists: Michael Clark, PhD—Consultant: BioTie Therapies Corp, BTG Plc, Cambridge University Technical Services (CUTS) Ltd, Celltech Therapeutics Ltd, Centocor, Inc Jean-Frederic Colombel, MD—Consultant: Boehringer-Ingelheim, Otsuka Pharmaceuticals, Protein Design Labs, Gruenenthal GMBH, Pharmion, UCB Pharmaceuticals/Celltech Therapeutics Ltd, Berlex/Schering-Plough, Centocor, Inc, Schering-Plough Corp, Elan Pharmaceuticals, Abbott Laboratories; Lectures: Centocor, Inc, Schering-Plough Corp, Abbott Laboratories, Elan Pharmaceuticals, Ferring USA; Grant Support: Giuliani, AstraZeneca Pharmaceuticals, Ferring USA, Danisco, Sanofi, Ferring France Brian C. Feagan, MD—Grant/Research Support: Schering-Plough Corp, Otsuka Pharmaceuticals, Millenium Pharmaceuticals, Tillotts, Abbott Laboratories, Protein Design Labs, Boehringer-Ingelheim, Novartis, Centocor, Inc, Berlex; Consultant: Synta Pharmaceuticals, Millenium Pharmaceuticals, Schering Canada, Celltech Therapeutics Ltd, Centocor, Inc, Elan/Biogen, Serono, Janssen-Ortho, Protein Design Labs, Isis, Teva Pharmaceuticals, Santarus, Inc, Schering-Plough Corp; Speakers’ Bureau: AstraZeneca Pharmaceuticals; Member, Scientific Advisory Board: Protein Design Labs, AstraZeneca Pharmaceuticals, Elan/Biogen, Celltech, Synta Pharmaceuticals, Schering Canada; Stock Shareholder: Santarus, Inc Richard N. Fedorak, MD—Consultant, Speakers’ Bureau, or Grant Funding: Abbott, Schering, Elan, USB, BMS, Centocor Stephen B. Hanauer, MD—Consultant: Centocor, Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma, Millenium Pharmaceuticals, Berlex Laboratories, Bristol-Meyers-Squibb; Research Support: Centocor, Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma, BMS; Lecture Honorarium: Centocor, Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma Michael A. Kamm, MD, PhD—Consultant: Abbott, Elan, Schering-Plough, UCB Lloyd Mayer, MD—Consultant: Centocor, Inc, Abbott Laboratories, Protein Design Labs, Prometheus Labs, Salix Carol Regueiro, MD—No financial relationships to disclose. Paul Rutgeerts, MD—Speakers’ Bureau: Biogen Idec, Centocor, Inc, Elan Pharmaceuticals, Schering-Plough Corp; Advisor: Centocor, Inc, Schering-Plough Corp; Consultant: Millenium Pharmaceuticals, Protein Design Labs, Centocor, Schering-Plough, UCB Pharma, Abbott Laboratories, Bristol-Myers Squibb; Research support: Centocor, Schering-Plough, Abbott, UCB; Lecture honorarium: Centocor, Inc, Schering-Plough Corporation, UCB Pharma, Abbott Laboratories, Protein Design Labs. William J. Sandborn, MD—Research Support: Centocor, Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma; Consultant: Centocor, Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma, Millenium Pharmaceuticals, Cerimon Pharmaceuticals, Isis Pharmaceuticals, Berlex Laboratories; Continuing Medical Education Unrestricted Grants: Centocor Abbott Laboratories, UCB Pharma, Elan Pharmaceuticals, PDL Biopharma Bruce E. Sands, MD—Consultant: Centocor, Biogen/IDEC, Elan, Abbott Laboratories, Prometheus Laboratories, Shire Pharmaceuticals, Berlex, Protein Design Laboratories Biopharma, Otsuka America Pharmaceuticals Inc, Solvay Pharmaceuticals, Procter & Gamble Pharmaceuticals, Synta Pharmaceuticals, Avidia, Cerimon Pharmaceuticals, Bristol-Myers Squibb, Osiris, Millenium Pharmaceuticals; Research Support: Centocor, Elan, Abbott Laboratories, Prometheus Laboratories, Berlex, Otsuka, Synta Pharmaceuticals, Millenium Pharmaceuticals; Lectures: Centocor, Abbott Laboratories, Shire Pharmaceuticals, Berlex, Otsuka America Pharmaceuticals Inc, Procter & Gamble Pharmaceuticals Stefan Schreiber, MD—Grant/Research Support: Centocor, Inc, Schering-Plough Corp, UCB Pharmaceuticals; Consultant: UCB Pharmaceuticals, Schering-Plough Corp, Elan Pharmaceuticals, Abbott Laboratories, Teva Pharmaceuticals, Boehringer-Ingelheim; Major Stock Shareholder: Conan’s AG Stephan Targan, MD—Consultant: Scientific Advisory Board, Santarus, Inc, Protein Design Labs; Major Stock Shareholder: Prometheus Labs, Santarus, Inc; Other: Member, Board of Directors, Prometheus Labs Simon Travis, MD—Adviser, Lecturer, Unrestricted Educational Grants, or Research Support: Abbott, Centocor, Schering Plough, UCB Severine Vermeire, MD, PhD—Grants/Research Support: UCB; Consultancy: Astra-Zeneca, Ferring; Speakers’ Bureau: Schering-Plough, Abbott, Ferring, UCB; Advisory Committee: Shire, Ferring PII: S0016-5085(07)00988-2 doi:10.1053/j.gastro.2007.05.006 © 2007 AGA Institute. Published by Elsevier Inc. All rights reserved. | |
|
ABSTRACT